Edition:
United Kingdom

Matthias Blamont

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

22 Nov 2019

PARIS Sanofi's most senior strategy boss is set to leave by the end of the month, according to a memo seen by Reuters, in the first major management change under new chief executive Paul Hudson as he shakes up the firm's priorities.

Sanofi weighing options for consumer healthcare unit: sources

21 Nov 2019

FRANKFURT/PARIS Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month.

Sanofi confident for 2019 despite third-quarter sales slip

31 Oct 2019

PARIS Sanofi expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care and vaccines businesses.

French weight-loss pill scandal set for landmark trial

20 Sep 2019

PARIS A landmark French trial will from next week seek to settle one of the country's biggest pharmaceutical scandals, probing whether the company behind a weight-loss drug believed to have triggered killer side-effects covered up the risks.

Paris commuters hit by transport strike over pension overhaul

13 Sep 2019

PARIS, Sept 13 Parisian commuters faced travel chaos on Friday as transport workers went on strike over plans to reduce their retirement privileges in a challenge to President Emmanuel Macron's pension reform plans.

EssilorLuxottica sets sights on retail dominance with $8 billion GrandVision deal

31 Jul 2019

PARIS EssilorLuxottica is buying Dutch opticians group GrandVision for up to 7.2 billion euros ($8 billion) in cash to take control of thousands of stores where it sells spectacles and lenses.

Sanofi raises outlook after strong second quarter

29 Jul 2019

PARIS Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

Eurofins to slow pace of M&A, expand in emerging markets

08 Jul 2019

PARIS Laboratory-testing company Eurofins Scientific plans to slow its frantic dealmaking pace in the next two years while also expanding in emerging markets to maintain double-digit sales growth over the next decade, its finance director said.

World News